The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: A systematic review

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 6, 2013, Pages 597-618

  Ungar, Wendy J ^a,b   Costa, Vania ^a   Burnett, Heather F ^a   Feldman, Brian M ^a,b,c,d   Laxer, Ronald M ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biologics; Juvenile idiopathic arthritis; Systematic review; TNF alpha blockers

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL RESPONSE MODIFIER; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ANAPHYLAXIS; ANKLE EDEMA; ARTICLE; BACTERIAL MENINGITIS; CONVULSION; CYTOMEGALOVIRUS INFECTION; DENGUE; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; ERYSIPELAS; GASTROENTERITIS; HALLUCINATION; HEPATITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LEG EDEMA; LUNG TUBERCULOSIS; NEPHRITIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OPEN STUDY; PAPILLITIS; PERSONALITY DISORDER; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESPIRATORY TRACT INFECTION; RETROBULBAR OPTIC NEUROPATHY; SEIZURE; SEPSIS; SYSTEMATIC REVIEW; TEMPORAL LOBE EPILEPSY; THYROID CANCER; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; COST-BENEFIT ANALYSIS; HUMANS; TREATMENT OUTCOME;

EID: 84881244714     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.10.006     Document Type: Article

References (82)

1. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369(9563):767-778.
2. Kulas D.T., Schanberg L. Juvenile idiopathic arthritis. Curr Opin Rheumatol 2001, 13(5):392-398.
3. Borchers A.T., Selmi C., Cheema G., Keen C.L., Shoenfeld Y., Gershwin M.E. Juvenile idiopathic arthritis. Autoimmun Rev 2006, 5:279-298.
4. Johnson C.J., Reilly K.M., Murray K.M. Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother 2001, 35:464-471.
5. Wilkinson N., Jackson G., Gardner-Medwin J. Biologic therapies for juvenile arthritis. Arch Dis Child 2003, 88(3):186-191.
6. Bowyer S.L., Roettcher P.A., Higgins G.C., Adams B., Myers L.K., Wallace C., et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 2003, 30(2):394-400.
7. McCann L.J., Wedderburn L.R., Hasson N. Juvenile idiopathic arthritis. Arch Dis Child Educ Pract Ed 2006, 91(2):ep29-ep36.
8. Kuemmerle-Deschner J.B., Horneff G. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007, 28(2):153-156.
9. McCann L.J., Woo P. Biologic therapies in juvenile idiopathic arthritis: why and for whom?. Acta Reumatol Port 2007, 32(1):15-26.
10. Laxer R.M., Harrison C. Bioethical issues in autologous stem cell transplantation in children and adults with arthritis. J Rheumatol 2001, 28(10):2147-2150.
11. Ruperto N., Murray K.J., Gerloni V., Wulffraat N., de Oliveira S.K., Falcini F., et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50(7):2191-2201.
12. Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., DeWitt E.M., et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011, 63(4):465-482.
13. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342(11):763-769.
14. Dhillon S., Lyseng-Williamson K.A., Scott L.J. Etanercept. A review of its use in the management of rheumatoid arthritis. Drugs 2007, 67(8):1211-1241.
15. Guthrie B., Rouster-Stevens K.A., Reynolds S.L. Review of medications used in juvenile rheumatoid arthritis. Pediatr Emergency Care 2007, 23(1):38-46.
16. Kalliolias G.D., Liossis S.C. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic juvenile idiopathic arthritis. Expert Opin Invest Drugs 2008, 17(3):349-359.
17. Fain O. Les inhibiteurs du TNF-α. Les indications s'étendent. La Rev Pract 2003, 53:1989-1990.
18. Jackson G. TNF-α inhibitors. Dermatol Ther 2007, 20:251-264.
19. Haines K.A. Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis 2007, 65(3):205-211.
20. Carmona L. Cambios entre anti-TNF, estan siempre justificados?. Reumatol Clin 2008, 4(3):87-89.
21. Rigby W.F.C. Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications?. Semin Arthritis Rheum 2005, 34(5 Suppl 1):1-2.
22. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Siegel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46(10):2565-2570.
23. Horneff G. Biologics for treatment of juvenile idiopathic arthritis-update 2007. Akt Rheumatol 2007, 32:128-135.
24. Quarta L., Corrado A., Melillo N., Cantatore F.P. Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann Intern Med 2005, 20(4):211-217.
25. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Sieper J., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007, 66(Suppl 3):2-22.
26. Grainger R., Harrison A.T.N.F. inhibitors for inflammatory arthritis in New Zealand. N Z Med J 2005, 118(1224):U1706.
27. Fleischmann R., Iqbal I., Nandeshwar P., Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002, 25(3):173-197.
28. Adib N., Simlman A., Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis: I. Frequency of different outcomes. Rheumatology 2005, 44:995-1001.
29. Ungar W.J., Costa V., Hancock-Howard R.L., Feldman B., Laxer R.M. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease modifying anti-rheumatic drugs. Arthritis Care Res 2011, 63(1):111-119.
30. Giannini E.H., Ruperto N., Ravelli A., Lovell D.J., Felson D.T., Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40(7):1202-1209.
31. Ruperto N., Lovell D.J., Cuttica R., Wilkinson N., Woo P., Espada G., et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007, 56(9):3096-3106.
32. Hashkes P.J., Laxer R.M. Medical treatment of juvenile idiopathic arthritis. JAMA 2005, 294(13):1671-1684.
33. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003, 48(1):218-226.
34. Lovell D.J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359(8):810-820.
35. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Perez N., Silva C.A., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008, 372(9636):383-391.
36. Google Translate. Google Inc. Available at: http://translate.google.com. Accessed June 2012.
37. Sauvain M.J., Schalm S.B., Berthet G., Bolz D., Cannizzaro E., Hofer M., et al. Swiss Registry for TNF-alpha blockers in children and adolescents with rheumatological diseases. Schweiz Rundsch Med Prax 2010, 99(11):649-654. [German].
38. De Inocencio Arocena J., Merino Munoz R., Alvarez Madrid C., Garcia-Consuegra Molina J. Efficacy of etanercept in the treatment of juvenile idiopathic arthritis. Ann Pediatr 2009, 70(4):354-361. [Spanish].
39. De Marco G., Gerloni V., Pontikaki I., Luriati A., Teruzzi B., Salmaso A., et al. Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy. Reumatismo 2007, 59(1):50-56.
40. Jadad A.R., Moore R.A., Carrol D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin Trials 1996, 17:1-12.
41. Public Health Resource Unit NHS. Cohort studies: 12 questions to help you make sense of a cohort study, 2004 [accessed April 2012]. http://www.sph.nhs.uk/sph-files/casp-appraisal-tools/cohort%2012%20questions.pdf.
42. Oxford Centre for Evidence-based Medicine. Levels of evidence, 2009 [accessed April 2012]. http://www.cebm.net/index.aspx?o=1025.
43. Ilowite N., Porras O., Reiff A., Rudge S., Punaro M., Martin A., et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009, 28(2):129-137. [Multicenter Study, Randomized Controlled Trial, Research Support, Non-US Gov't].
44. Wallace C.A., Giannini E.H., Spalding S.J., Hashkes P.J., O'Neil K.M., Zeft A.S., et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012, 64(6):2012-2021. [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-US Gov't].
45. Tynjala P., Vahasalo P., Tarkiainen M., Kroger L., Aalto K., Malin M., et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 2011, 70(9):1605-1612.
46. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P.M., Silman A.J. Outcomes after switching from one anti-tumor necrosis factor alfa agent to a second anti-tumor necrosis factor alfa agent in patients with rheumatoid arthritis. Results from a large UK national cohort study. Arthritis Rheum 2007, 56(1):13-20.
47. Giannini E.H., Ilowite N.T., Lovell D.J., Wallace C.A., Rabinovich C.E., Reiff A., et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009, 60(9):2794-2804.
48. Horneff G., De Bock F., Foeldvari I., Girschick H.J., Michels H., Moebius D., et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009, 68(4):519-525.
49. Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, et al. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials. Mod Rheumatol 2011;21(6):572-8.
50. Papsdorf V., Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology 2011, 50(1):214-221. [Research Support, Non-U.S. Gov't].
51. Sevcic K., Orban I., Brodszky V., Bazso A., Balogh Z., Poor G., et al. Experiences with tumour necrosis factor-alpha inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology 2011, 50(7):1337-1340.
52. Southwood T.R., Foster H.E., Davidson J.E., Hyrich K.L., Cotter C.B., Wedderburn L.R., et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011, 50(1):189-195. [Research Support, Non-US Gov't].
53. Zuber Z., Rutkowska-Sak L., Postepski J., Dobrzyniecka B., Opoka-Winiarska V., Kobusinska K., et al. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit 2011, 17(12):SR35-SR42.
54. Otten M.H., Prince F.H., Twilt M., van Rossum M.A., Armbrust W., Hoppenreijs E.P., et al. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2010, 37(3):665-667.
55. Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 2009;30(2):229-38.
56. Horneff G., Minden K., Kuemmerle-Deschner J., Thon A., Girschick H.J., Huppertz H.I. Safety and efficacy of once weekly etanercept 0.8mg/kg: interim analysis of a multicentre 12 weeks open trial in active juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67(Suppl II):268.
57. Prince F.H.M., Twilt M., Rt Cate, van Rossum M.A.J., Armbrust W., Hoppenreijs E.P.A.H., et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009, 68(5):635-641.
58. Lovell D.J., Reiff A., Ilowite N.T., Wallace C.A., Chon Y., Lin S.L., et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008, 58(5):1496-1504.
59. Nielsen S., Ruperto N., Gerloni V., Simonini G., Cortis E., Lepore L., et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008, 26(4):688-692.
60. Lovell D.J., Reiff A., Jones O.Y., Schneider R., Nocton J., Stein L.D., et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006, 54(6):1987-1994.
61. Mori M., Takei S., Imagawa T., Imanaka H., Maeno N., Kurosawa R., et al. Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Mod Rheumatol 2005, 15(6):397-404.
62. Horneff G., Schmeling H., Biedermann T., Foeldvari I., Ganser G., Girschick H.J., et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63(12):1638-1644.
63. Quartier P., Taupin P., Bourdeaut F., Lemelle I., Pillet P., Bost M., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48(4):1093-1101.
64. Bracaglia C., Buonuomo P.S., Tozzi A.E., Pardeo M., Nicolai R., Campana A., et al. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol 2012, 39(6):1287-1290.
65. Ruperto N., Lovell D.J., Cuttica R., Woo P., Meiorin S., Wouters C., et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010, 69(4):718-722.
66. Gerloni V., Pontikaki I., Gattinara M., Desiati F., Lupi E., Lurati A., et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005, 52(2):548-553.
67. Lamot L., Bukovac L.T., Vidovic M., Frleta M., Harjacek M. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2011, 29(1):131-139.
68. Tynjala P., Vahasalo P., Honkanen V., Lahdenne P. Drug survival of the first and second course of antitumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009, 68(4):552-557.
69. Gerloni V., Pontikaki I., Gattinara M., Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008, 67(8):1145-1152.
70. Trachana M., Pratsidou-Gertsi P., Pardalos G., Kozeis N., Badouraki M., Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol 2011, 40(2):101-107.
71. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Perez N., Silva C.A., et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010, 62(6):1792-1802.
72. Alexeeva E.I., Valieva S.I., Bzarova T.M., Semikina E.L., Isaeva K.B., Lisitsyn A.O., et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011, 30(9):1163-1172.
73. Horneff G., Ebert A., Fitter S., Minden K., Foeldvari I., Kummerle-Deschner J., et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology 2009, 48(8):916-919.
74. Wallace C.A., Ruperto N., Giannini E.H. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290-2294.
75. Cimaz R., Prieur A.M. Advances in pediatric rheumatology. Future Rheumatol 2008, 3(3):239-251.
76. Gerloni V., Pontikaki I., Gattinara M., Fantini F. Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience. Reumatismo 2007, 59(3):244-261.
77. Broughton T., Armon K. Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus. Paediatr Drugs 2012, 14(1):7-12.
78. Quartier P. When should we use TNF antagonists in children with rheumatic disease?. Joint Bone Spine 2007, 74(1):1-3.
79. St. Clair E.W. Tides of inflammation: impact of biologics. J Rheumatol 2002, 29(Suppl 65):22-26.
80. Lin J., Ziring D., Desai S., Kim S., Wong M., Korin Y., et al. TNFα blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30.
81. Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today 2006, 42(9):559-576.
82. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371(9617):998-1006.